Current Report · Items 2.02, 9.01 · 8-K

Cellectar Biosciences, Inc.

CLRBNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 13, 2026, we issued a press release announcing our financial results for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

Filed Aug 13, 2026Accepted Aug 13, 2026, 7:25 AM EDTCIK 1279704Accession 0001104659-26-095460

View company →Permanent SEC source ↗

Press release in this filing

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates →

Company context

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.

Current securities

CLRBNASDAQ · EQUITY · Current

Historical securities (2)

CLRBWNASDAQ · WARRANT · Historical · closed Aug 21, 2019 CLRBZNASDAQ · WARRANT · Historical · closed Apr 16, 2021

Recent company filings

Registered securities in this filing

Cellectar Biosciences, Inc. · 8-K · Filed 2026-08-13

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.00001 per share

Symbol: CLRB
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-08-13

Dimensions: Not supplied

Accession 000110465926095460 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Filed exhibits (1)

EX-99.1 (by filename) tm2623056d1_ex99-1.htm

EX-99.1 2 tm2623056d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical Oncology 2026 Annual Meeting Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in Triple Negative Breast Cancer Announced Publication of Phase 1 Data in Peer-Reviewed Journal Cancers Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., August 13, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2026, and provided a corporate update. “Our second quarter marked another period of significant execution as we continued …

Open exhibit ↗

Get the free weekly BCS email.